597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer by Patrick Forde, Neru Munshi, Ugur Sahin, Oezlem Tuereci, Akin Atmaca, Petra Rietschel, Dániel Deme, Bala Öven, Erdem Göker, Istvan Lang, Patrick Brück, Michael Wenger, Thomas Schell, Kezi Ünsal-Kaçmaz, Janet Markman, Huyuan Yang